PT-141 (Bremelanotide) Reference Guide

Compound Reference Overview

Field Value
Name PT-141 (Bremelanotide)
Reference Code PT-141
Category Sexual Health / Melanocortin Receptor Agonist
Example Strength 10 mg vial (varies by formulation)
Reference Range 0.5–2 mg as needed (FDA-approved dose: 1.75 mg)
Frequency As needed, ≥45 minutes before activity (not more than once in 24 hours)
Key Safety Warning FDA limits to 8 doses per month. Nausea is common (~40%). May cause temporary skin hyperpigmentation and blood pressure changes.

Mechanism of Action (Educational)

PT-141 (Bremelanotide) is a melanocortin receptor agonist, primarily targeting MC4 receptors within the central nervous system.

Unlike PDE5 inhibitors, PT-141 acts centrally rather than peripherally. It increases sexual desire and arousal by modulating dopaminergic pathways involved in sexual motivation.

Indications (Regulatory / Off-Label)

  • FDA-approved: Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women (Vyleesi)
  • Off-label: Erectile dysfunction
  • Off-label: Low libido (men and women)

Administration (Clinical Use)

Parameter Details
Route Subcutaneous
Frequency As needed
Injection Sites Abdomen or thigh
Timing 45 minutes to 2 hours before sexual activity

Titration Schedule (Clinical Framework)

  • Week 1: 0.5–1 mg test dose
  • Week 2+: 1–2 mg as needed
  • FDA-approved dose: 1.75 mg
  • Maximum: 1 dose per 24 hours, 8 doses per month

Start low due to nausea risk. Pre-treatment with anti-emetic may be considered.

Pharmacokinetics (Literature)

  • Onset: 45 minutes to 2 hours
  • Half-life: ~2–3 hours
  • Peak response varies by individual

Reconstitution & Concentration (Mathematical Illustration Only)

Parameter Value
Diluent Bacteriostatic water (example only)
Reconstitution Volume 2 mL (example)
Resulting Concentration 5 mg/mL (5000 mcg/mL)
Stability Up to 28 days refrigerated (varies by formulation)

Reconstitution Math Example

  • 10 mg ÷ 2 mL = 5 mg/mL
  • 0.1 mL = 0.5 mg
  • 0.2 mL = 1.0 mg
  • 0.35 mL = 1.75 mg (FDA dose)

Provided strictly for arithmetic reference.

Mathematical Calculation Tool

The calculator below allows concentration and volume calculations based on vial strength and dilution volume. This tool is provided strictly for mathematical reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Safety & Contraindications (Summary)

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy or breastfeeding
  • Concurrent use of naltrexone

Drug Interactions

  • Naltrexone (high): significantly reduces efficacy
  • Antihypertensives (moderate): additive blood pressure effects

Adverse Events

  • Nausea (~40%)
  • Flushing
  • Headache
  • Injection site reactions
  • Skin hyperpigmentation

Serious Risks

  • Transient blood pressure elevation
  • Focal hyperpigmentation

Monitoring (Clinical Framework)

  • Blood pressure
  • Nausea severity
  • Skin changes

Disclaimer

Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Other uses are off-label. This content is provided strictly for educational and professional reference purposes. All clinical decisions must be made by a licensed healthcare professional.

Reference Sources